RECURSION PHARMACEUTICALS Business Summary

Recursion Pharmaceuticals, Inc. (RXRX) operates as a clinical-stage "TechBio" company that industrializes drug discovery through its Recursion OS, a proprietary platform integrating high-throughput biology, chemistry, and automated data science. The company generates revenue primarily through high-value strategic partnerships and collaboration agreements with pharmaceutical giants such as Roche, Genentech, and Sanofi, which provide upfront payments and tiered milestone-based fees. Its business is segmented into its internal pipeline, focusing on rare diseases and oncology (e.g., REC-994 and REC-4881), and its external collaboration segment, which leverages its 25-petabyte biological dataset to identify novel targets for partners. In the competitive landscape of AI-driven drug discovery, Recursion distinguishes itself by its massive vertical integration and recent acquisition of Exscientia, positioning it as a dominant platform-scale leader relative to peers like Schrödinger, Inc., AbCellera, and Relay Therapeutics. Recursion was co-founded by Dr. Chris Gibson, Dr. Blake Borgeson, and Dr. Dean Li, the latter of whom currently serves as President of Merck Research Labs. Effective January 1, 2026, the company underwent a strategic leadership transition with Najat Khan, Ph.D., assuming the role of CEO and President; Dr. Khan previously served as Chief Data Science Officer at Johnson & Johnson and was instrumental in the Exscientia merger. Co-founder Chris Gibson transitioned to Chairman of the Board, while Ben Taylor serves as Chief Financial Officer and Ben Mabey as Chief Technology Officer. The company’s board and investor base are bolstered by significant institutional backing and strategic ties, including notable board representation from DCVC’s Zachary Bogue and a high-profile equity investment from NVIDIA, reflecting its pedigree at the intersection of deep learning and biotechnology.